Compare Amphastar Pharmaceuticals Inc (AMPH) vs HSBC Holdings plc (HSBC) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

HSBC trades at $99.09, up 1.09% today and near its 52-week high of $99.47. The stock shows bullish technical signals with consistent earnings beats in recent quarters. Recent news highlights strategic moves, including a potential Turkey business sale and AI expansion with Google Cloud. Revenue is stable at $71.02B for 2025, with a net income margin of 30.81% and a P/E ratio of 16.38.

Outlook is cautiously optimistic, supported by earnings momentum and restructuring efforts. Risks include regulatory penalties and global economic sensitivity. Analysts are mixed, with 38.1% recommending buy. The dividend of $0.50 per share adds income appeal, but investors should monitor execution of strategic initiatives.